Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIMT-2 phase 3 study of peginterferon lambda-1a in chronic hepatitis D
MOH_2022-04-13_010674Phase 3Recruiting
- Sponsor
- Eiger BioPharmaceuticals, Inc.
- Start
- Apr 2022
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of peginterferon lambda-1a in hepatitis D (HDV) and hepatitis B (HBV) (2 arms), sponsored by Eiger BioPharmaceuticals, Inc. Primary endpoint: Reduction in HDV RNA in blood. Started Apr 2022; status: recruiting.
02
Drugs
peginterferon lambda-1a
03
Conditions
hepatitis D (HDV)hepatitis B (HBV)
Beyond the preview
Go deeper on MOH_2022-04-13_010674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-04-13_010674.